首頁(yè) > SCI期刊 > SCIE期刊 > JCRQ3 > 期刊介紹
評(píng)價(jià)信息:
影響因子:1.2
年發(fā)文量:19
《綜合醫(yī)學(xué)的進(jìn)展》(Advances In Integrative Medicine)是一本以INTEGRATIVE & COMPLEMENTARY MEDICINE綜合研究為特色的國(guó)際期刊。該刊由Elsevier出版商該刊已被國(guó)際重要權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。期刊聚焦INTEGRATIVE & COMPLEMENTARY MEDICINE領(lǐng)域的重點(diǎn)研究和前沿進(jìn)展,及時(shí)刊載和報(bào)道該領(lǐng)域的研究成果,致力于成為該領(lǐng)域同行進(jìn)行快速學(xué)術(shù)交流的信息窗口與平臺(tái)。該刊2023年影響因子為1.2。CiteScore指數(shù)值為3.2。
The Journal of Advances in Integrative Medicine is renowned for its high standards of scientific publication and rigorous review process. It adopts an international standard double-blind review system to ensure that each manuscript undergoes rigorous review by professional scholars and experts, ensuring the scientific, innovative, and reliable nature of its content. Its publication scope is extensive, covering multiple fields such as traditional Chinese and Western medicine and dietary therapy, joint research between traditional Chinese medicine and Western medicine, the latest developments in precision medicine, and the impact of genomics on disease prevention and treatment. It comprehensively focuses on the full lifecycle management of diseases, including new technologies, methods, and products related to disease occurrence and development, screening and early warning, diagnostic typing, treatment intervention, and prognosis.
In addition, the journal also focuses on the challenges and opportunities in the global health field, as well as the importance of equal access to healthcare for all, and is committed to promoting the development and popularization of integrated medicine on a global scale. Its international editorial team and open access publishing strategy further promote the widespread dissemination and collaborative exchange of academic achievements.
《綜合醫(yī)學(xué)的進(jìn)展雜志》以高標(biāo)準(zhǔn)的科學(xué)發(fā)表和嚴(yán)格的審稿流程著稱,采用國(guó)際標(biāo)準(zhǔn)的雙盲評(píng)審制度,確保每篇稿件都經(jīng)過(guò)專業(yè)學(xué)者和專家的嚴(yán)格審核,以保證內(nèi)容的科學(xué)性、創(chuàng)新性和可靠性。其發(fā)表范圍廣泛,涵蓋中西藥與膳食療法、中醫(yī)與西醫(yī)聯(lián)合研究、精準(zhǔn)醫(yī)學(xué)的最新發(fā)展、基因組學(xué)對(duì)疾病預(yù)防和治療的影響等多個(gè)領(lǐng)域,全面關(guān)注疾病的全生命周期管理,包括疾病的發(fā)生發(fā)展、篩查預(yù)警、診斷分型、治療干預(yù)及轉(zhuǎn)歸預(yù)后等方面的新技術(shù)、新方法和新產(chǎn)品。
此外,該期刊還關(guān)注全球衛(wèi)生領(lǐng)域的挑戰(zhàn)和機(jī)遇,以及人人平等享有醫(yī)療保健的重要性,致力于推動(dòng)綜合醫(yī)學(xué)在全球范圍內(nèi)的發(fā)展與普及。其國(guó)際化的編委團(tuán)隊(duì)和開放獲取的出版策略,進(jìn)一步促進(jìn)了學(xué)術(shù)成果的廣泛傳播與合作交流。
如果您需要協(xié)助投稿或潤(rùn)稿服務(wù),您可以咨詢我們的客服老師。我們專注于期刊投稿服務(wù)十年,熟悉發(fā)表政策,可為您提供一對(duì)一投稿指導(dǎo),避免您在投稿時(shí)頻繁碰壁,節(jié)省您的寶貴時(shí)間,有效提升發(fā)表機(jī)率,確保SCI檢索(檢索不了全額退款)。我們視信譽(yù)為生命,多方面確保文章安全保密,在任何情況下都不會(huì)泄露您的個(gè)人信息或稿件內(nèi)容。
JCR分區(qū)等級(jí):Q3
按JIF指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:INTEGRATIVE & COMPLEMENTARY MEDICINE | ESCI | Q3 | 28 / 43 |
36% |
按JCI指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:INTEGRATIVE & COMPLEMENTARY MEDICINE | ESCI | Q3 | 30 / 43 |
31.4% |
Gold OA文章占比 | 研究類文章占比 | 文章自引率 |
4.17% | 100.00% | |
開源占比 | 出版國(guó)人文章占比 | OA被引用占比 |
名詞解釋:JCR分區(qū)在學(xué)術(shù)期刊評(píng)價(jià)、科研成果展示、科研方向引導(dǎo)以及學(xué)術(shù)交流與合作等方面都具有重要的價(jià)值。通過(guò)對(duì)期刊影響因子的精確計(jì)算和細(xì)致劃分,JCR分區(qū)能夠清晰地反映出不同期刊在同一學(xué)科領(lǐng)域內(nèi)的相對(duì)位置,從而幫助科研人員準(zhǔn)確識(shí)別出高質(zhì)量的學(xué)術(shù)期刊。
CiteScore | SJR | SNIP | CiteScore 指數(shù) | ||||||||
3.2 | 0.329 | 0.493 |
|
名詞解釋:CiteScore是基于Scopus數(shù)據(jù)庫(kù)的全新期刊評(píng)價(jià)體系。CiteScore 2021 的計(jì)算方式是期刊最近4年(含計(jì)算年度)的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。CiteScore基于全球最廣泛的摘要和引文數(shù)據(jù)庫(kù)Scopus,適用于所有連續(xù)出版物,而不僅僅是期刊。目前CiteScore 收錄了超過(guò) 26000 種期刊,比獲得影響因子的期刊多13000種。被各界人士認(rèn)為是影響因子最有力的競(jìng)爭(zhēng)對(duì)手。
歷年IF值(影響因子)
歷年引文指標(biāo)和發(fā)文量
歷年自引數(shù)據(jù)
若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商。